Asset
Sabizabulin
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04844749 | phase3 | terminated | 2021-06-24 | 2023-05-04 | Veru Inc. | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent |
| NCT03752099 | phase1_2 | terminated | 2019-01-18 | 2023-03-15 | Veru Inc. | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer |
| NCT04842747 | phase3 | completed | 2021-05-18 | 2022-07-06 | Veru Inc. | VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study |
FDA applications (0)
This company has no applications containing this asset.